/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Bio Path Holdings Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.2 -0.6684(-66.84%) BPTH at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 0.1951
Highest Today 0.3645
Today’s Open 0.3645
Prev. Close 0.6332
52 Week High 9.83
52 Week Low 0.20
Day’s Range: Low 0.1951 High 0.3645
52-Week Range: Low 0.20 High 9.83
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -68.65
3 year return -99.27
5 year return -99.68
10 year return -

Institutional Holdings

Apollon Wealth Management, LLC 0.26

Geode Capital Management, LLC 0.24

Vanguard Group Inc 0.23

Vanguard Institutional Extnd Mkt Idx Tr 0.23

Fidelity Extended Market Index 0.21

Citadel Advisors Llc 0.19

Tower Research Capital LLC 0.06

UBS Group AG 0.05

BlackRock Inc 0.04

NT Ext Equity Mkt Idx Fd - NL 0.01

Fidelity Series Total Market Index 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

NT Ext Eq Mkt Indx Fd DC Lend T4 0.00

Tradewinds Capital Management, LLC 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

Morgan Stanley - Brokerage Accounts 0.00

Bank of America Corp 0.00

Group One Trading, LP 0.00

BNYM Mellon SL Market Completion UC1 0.00

Northern Trust Wilshire 5000 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Global Retirement Partners, LLC. 0.00

SSgA U.S. Total Market Index Strategy 0.00

Armistice Capital, LLC 0.00

Blackstone Alternative Multi-Strategy I 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Hanson Mcclain Inc 0.00

HRT FINANCIAL LLC 0.00

Qube Research & Technologies 0.00

Virtu Financial LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.65 M

PB Ratio 2.335

PE Ratio 0.0

Enterprise Value 3.12 M

Total Assets 3.22 M

Volume 6930475

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-16672000 -16.7M, FY22:-13835000 -13.8M, FY21:-10437000 -10.4M, FY20:-10856000 -10.9M, FY19:-8505000 -8.5M

Quarterly Revenue Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:0 0.0M, Q4/2023:274000 0.3M, Q3/2023:0 0.0M

Quarterly Profit Q3/2024:null 0.0M, Q2/2024:-32000 -0.0M, Q1/2024:-47000 -0.0M, Q4/2023:233000 0.2M, Q3/2023:null 0.0M

Quarterly Net worth Q3/2024:-2115000 -2.1M, Q2/2024:-1869000 -1.9M, Q1/2024:-3157000 -3.2M, Q4/2023:-3372000 -3.4M, Q3/2023:-3199000 -3.2M

Fund house & investment objective

Company Information Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Organisation Biotechnology

Employees 10

Industry Biotechnology

CEO Mr. Peter H. Nielsen MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow